Advertisement

Topics

Chiesi Group Company Profile

12:24 EDT 28th July 2016 | BioPortfolio

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.

Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.

Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.

Location

Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,
Parma
43100
Italy

Contact

Phone: 39 0521 2791
Fax: 39 0521 774468
Email: info@chiesigroup.com


News Articles [545 Associated News Articles listed on BioPortfolio]

Medicines Company Sells Three Heart Meds to Italy's Chiesi

The company divests Cleviprex, Kengreal and rights to Argatroban for Injection to Chiesi USA Inc.

Chiesi reports significant international growth in 2015

Italian family-owned drugmaker Chiesi Farmaceutici closed 2015 on a high note by reporting annual turnover…

Chiesi to Acquire 3 Hospital Products - Kengreal(R), Cleviprex(R), Argatroban for Injection

PARMA, ITALY--(Marketwired - May 09, 2016) -  Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have agreed to acquire worldwide rig...

Chiesi nears cardiovascular assets deal with Medicine Co: sources

(Reuters) - Italian specialty pharmaceutical company Chiesi Farmaceutici SpA is close to an agreement to acquire some of Medicines Co's cardiovascular assets for several hundred millions of dollars, ...

Chiesi nears cardiovascular assets deal with Medicine Co-sources

May 8 (Reuters) - Italian specialty pharmaceutical company Chiesi Farmaceutici SpA is close to an agreement to acquire some of Medicines Co's cardiovascular assets for several hundred millions of doll...

Chiesi acquires three cardiovascular assets from The Medicines Co.

The Medicines Co. divested three non-core cardiovascular assets--Cleviprex (clevidipine), Kengreal (cangrelor), and argatroban for injection (50mg/50ml)--to Chiesi Farmaceutici SPA.

Chiesi Completes the Acquisition of Three Hospital Products -- Kengreal(R), Cleviprex(R) and Argatroban(TM) for Injection

PARMA, ITALY--(Marketwired - June 22, 2016) - Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have finalized the acquisition of multina...

UPDATE 1-Medicines Co to sell some cardiovascular drugs to Italy's Chiesi

May 9 (Reuters) - The Medicines Co is selling some of its cardiovascular drugs to Italy's Chiesi Farmaceutici SpA for up to $792 million as the U.S. company looks to raise money for drug development. ...

PubMed Articles [2453 Associated PubMed Articles listed on BioPortfolio]

Improvement of the Marginal Reflex Distance-1 in Blepharoptosis Surgeries.

The aim of this study was to predict the improvement of the marginal reflex distance (MRD1) in each blepharoptosis surgery.In PubMed and Scopus, the search terms 1. (blepharoptosis) AND 2. (surgery) A...

I won't tell: Young children show loyalty to their group by keeping group secrets.

Group loyalty is highly valued. However, little is known about young children's loyal behavior. This study tested whether 4- and 5-year-olds (N=96) remain loyal to their group even when betraying it w...

Three new species of Macrelmis Motschulsky (Coleoptera: Elmidae: Elminae) from Southeastern Brazil with new definition of species groups to the genus.

Three new species of Macrelmis Motschulsky, 1859 are described and illustrated based on adult males from Rio de Janeiro, Minas Gerais and São Paulo states (southeastern Brazil). A new species groups ...

Protective effects of udenafil citrate, piracetam and dexmedetomidine treatment on testicular torsion/detorsion-induced ischaemia/reperfusion injury in rats.

The aim of this study was to investigate the antioxidant properties of udenafil citrate (1.4 mg kg(-1) -2.8 mg kg(-1) ), dexmedetomidine 25 μg kg(-1) and piracetam 200 mg kg(-1) administered ...

Evaluation of group A1B erythrocytes converted to type as group O: studies of markers of function and compatibility.

Enzymatic conversion of blood group A1B red blood cells (RBC) to group O RBC (ECO) was achieved by combined treatment with α-galactosidase and α-N-acetylgalactosaminidase. The aim of this study was ...

Clinical Trials [2319 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?

The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...

Companies [1534 Associated Companies listed on BioPortfolio]

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Chiesi Group" on BioPortfolio

We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Bioethics
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...


Corporate Database Quicklinks



Searches Linking to this Company Record